Aditya Bardia, MD, MPH - Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?

Please visit answersincme.com/YZZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses estrogen receptor–positive breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for investigating oral selective estrogen receptor degraders (SERDs) for the treatment of ER-positive early breast cancer; Review the clinical profiles of emerging oral SERDs for the treatment of patients with ER-positive early breast cancer; and Outline clinical approaches where oral SERDs may be appropriate based on their clinical profile in ER-positive early breast cancer.